Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Nov;61(11):992-9.
doi: 10.1136/thx.2005.045195.

Asthma exacerbations . 4: Prevention

Affiliations
Review

Asthma exacerbations . 4: Prevention

J M FitzGerald et al. Thorax. 2006 Nov.

Abstract

Asthma exacerbations are common. They account for a significant morbidity and contribute a disproportionate amount to the cost of asthma management. The optimal strategies for the prevention of asthma exacerbations include the early introduction of anti-inflammatory treatment-most commonly, low dose inhaled corticosteroids. This should be coupled with a structured education programme which has a written action plan as an integral component. Where patients continue to be poorly controlled, the addition of a long acting beta agonist should be considered. The latter should not be used as monotherapy and should always be used with inhaled corticosteroids. Atopic patients with a history of repeated exacerbations, especially if they are steroid dependent and with a raised IgE, may be considered as potential candidates for omalizumab. In the early stages of an asthma exacerbation, doubling the dose of inhaled corticosteroids has been shown to be ineffective. The ideal strategy for the management of worsening asthma in patients on combination treatment, especially salmeterol and fluticasone, is uncertain. There is an emerging body of evidence for strategies on how to prevent progression to an exacerbation in patients taking a combination of budesonide and formoterol.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JMF has received research funding and consultant fees as a member of advisory boards and speaking panels for the following companies: AstraZeneca, GlaxoSmithKline, Novartis, Altana, Schering, Hofmann Le Roche. PGG has participated in clinical trials of asthma therapies funded by GlaxoSmithKline, AstraZeneca, Pharmaxis, Novartis, and NHMRC Australia.

References

    1. Tattersfield A E, Postma D S, Barnes P J.et al Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999160594–599. - PubMed
    1. Pauwels R A, Pederesen S, Busse W W.et al Early intervention with budesonide in mild persistent asthma: a randomized double‐blind trial. Lancet 20033611071–1076. - PubMed
    1. Awadh N, Grunfeld A, FitzGerald J M. Health care costs associated with acute asthma. A prospective economic analysis. Can Respir J 19996521–525. - PubMed
    1. FitzGerald J M. Acute asthma. BMJ 2001323841–845. - PMC - PubMed
    1. Aldington S, Beasley R. Asthma exacerbations · 5: Assessment and management of severe asthma in adults in hospital. Thorax 200661 (in press) - PMC - PubMed

Publication types

MeSH terms

Substances